Aligos Therapeutics, Inc. Operating Cash Flow
Aligos Therapeutics, Inc. (ALGS) reported Operating Cash Flow of -$48.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Aligos Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$24.95M.
- Aligos Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$23.13M.
- Aligos Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$21.75M.
- Aligos Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$24.34M.
- Aligos Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$82.50M.
- Aligos Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$80.74M.
- Aligos Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$79.00M.
- Aligos Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$79.39M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$24.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$48.08M 10-Q · filed 2026-08-06 | -$69.82M derived: sum of 3 quarters · filed 2026-08-06 | -$94.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$23.13M 10-Q · filed 2026-05-07 | -$44.87M derived: sum of 2 quarters · filed 2026-05-07 | -$69.22M derived: sum of 3 quarters · filed 2026-05-07 | -$84.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$21.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$46.09M derived: sum of 2 quarters · filed 2026-03-05 | -$61.59M derived: sum of 3 quarters · filed 2026-08-06 | -$82.50M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$24.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$39.85M derived: sum of 2 quarters · filed 2026-08-06 | -$60.76M 10-Q · filed 2025-11-06 | -$79.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$15.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$36.41M 10-Q · filed 2026-08-06 | -$54.82M derived: sum of 3 quarters · filed 2026-08-06 | -$74.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$20.91M 10-Q · filed 2026-05-07 | -$39.31M derived: sum of 2 quarters · filed 2026-05-07 | -$59.41M derived: sum of 3 quarters · filed 2026-05-07 | -$78.91M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$18.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$38.50M derived: sum of 2 quarters · filed 2026-03-05 | -$58.00M derived: sum of 3 quarters · filed 2026-03-05 | -$80.74M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$20.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$39.59M derived: sum of 2 quarters · filed 2025-11-06 | -$62.34M 10-Q · filed 2025-11-06 | -$85.00M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$19.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$42.24M 10-Q · filed 2025-08-06 | -$64.90M derived: sum of 3 quarters · filed 2025-08-06 | -$85.23M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$22.75M 10-Q · filed 2025-05-06 | -$45.40M derived: sum of 2 quarters · filed 2025-05-06 | -$65.74M derived: sum of 3 quarters · filed 2025-05-06 | -$79.36M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$22.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$42.99M derived: sum of 2 quarters · filed 2025-03-10 | -$56.61M derived: sum of 3 quarters · filed 2025-03-10 | -$79.00M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$20.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$33.95M derived: sum of 2 quarters · filed 2024-11-06 | -$56.34M 10-Q · filed 2024-11-06 | -$73.12M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$13.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$36.00M 10-Q · filed 2024-08-06 | -$52.79M derived: sum of 3 quarters · filed 2024-08-06 | -$69.92M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$22.39M 10-Q · filed 2024-05-07 | -$39.17M derived: sum of 2 quarters · filed 2024-05-07 | -$56.31M derived: sum of 3 quarters · filed 2024-05-07 | -$81.34M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$16.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$33.92M derived: sum of 2 quarters · filed 2024-03-12 | -$58.95M derived: sum of 3 quarters · filed 2024-03-12 | -$79.39M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$17.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$42.17M derived: sum of 2 quarters · filed 2023-11-02 | -$62.61M 10-Q · filed 2023-11-02 | -$100.09M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$25.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$45.47M 10-Q · filed 2023-08-03 | -$82.95M derived: sum of 3 quarters · filed 2023-08-03 | -$108.32M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$20.43M 10-Q · filed 2023-05-04 | -$57.91M derived: sum of 2 quarters · filed 2023-05-04 | -$83.28M derived: sum of 3 quarters · filed 2023-05-04 | -$106.30M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$37.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$62.85M derived: sum of 2 quarters · filed 2023-03-09 | -$85.87M derived: sum of 3 quarters · filed 2023-03-09 | -$115.66M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$25.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$48.39M derived: sum of 2 quarters · filed 2022-11-02 | -$78.18M 10-Q · filed 2022-11-02 | -$97.87M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | -$23.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$52.81M 10-Q · filed 2022-08-04 | -$72.50M derived: sum of 3 quarters · filed 2022-08-04 | -$89.06M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$29.80M 10-Q · filed 2022-05-04 | -$49.48M derived: sum of 2 quarters · filed 2022-05-04 | -$66.05M derived: sum of 3 quarters · filed 2022-05-04 | -$83.74M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$19.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$36.25M derived: sum of 2 quarters · filed 2022-03-10 | -$53.94M derived: sum of 3 quarters · filed 2022-03-10 | -$74.26M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$16.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$34.26M derived: sum of 2 quarters · filed 2021-11-04 | -$54.58M 10-Q · filed 2021-11-04 | -$69.60M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$17.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$38.01M 10-Q · filed 2021-08-05 | -$53.03M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$20.32M 10-Q · filed 2021-05-10 | -$35.34M derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | -$15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | -$46.77M 10-K · filed 2021-03-23 | ||
| 2019-09-30 | -$31.75M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |